1.Efficacy and feasibility of catheter-based adrenal ablation on Cushing's syndrome associated hypertension.
Zhen Cheng YAN ; Nan JIANG ; He Xuan ZHANG ; Qing ZHOU ; Xiao Li LIU ; Fang SUN ; Ruo Mei YANG ; Hong Bo HE ; Zhi Gang ZHAO ; Zhi Ming ZHU
Chinese Journal of Cardiology 2023;51(11):1152-1159
Objective: To explore the value of catheter-based adrenal ablation in treating Cushing's syndrome (CS)-associated hypertension. Methods: A clinical study was conducted in patients with CS, who received catheter-based adrenal ablation between March 2018 and July 2023 in Daping Hospital. Parameters monitored were blood pressure (outpatient and 24-hour ambulatory), body weight, clinical characteristics, serum cortisol and adrenocorticotropic hormone (ACTH) at 8 am, 24-hour urinary free cortisol (24 h UFC), fasting blood glucose and postoperative complications. Procedure effectiveness was defined as blood pressure returning to normal levels (systolic blood pressure<140 mmHg (1 mmHg=0.133 kPa) and diastolic blood pressure<90 mmHg), cortisol and 24 h UFC returning to normal and improvement of clinical characteristics. The parameters were monitored during follow up in the outpatient department at 1, 3, 6, and 12 months after catheter-based adrenal ablation. Results: A total of 12 patients (aged (40.0±13.2) years) were reviewed. There were 5 males, with 5 cases of adenoma and 7 with hyperplasia from imaging studies. Catheter-based adrenal ablation was successful in all without interruption or surgical conversion. No postoperative complication including bleeding, puncture site infection, adrenal artery rupture or adrenal bleeding was observed. The mean follow up was 28 months. Compared to baseline values, body weight declined to (59.48±11.65) kg from (64.81±10.75) kg (P=0.008), fasting blood glucose declined to (4.54±0.83) mmol from (5.53±0.99) mmol (P=0.044), outpatient systolic blood pressure declined to (128±21) mmHg from (140±19) mmHg (P=0.005), diastolic blood pressure declined to (78±10) mmHg from (86±11) mmHg (P=0.041), and the mean ambulatory daytime diastolic blood pressure declined to (79±12) mmHg from (89±8) mmHg (P=0.034). Catheter-based adrenal ablation in 8 patients was defined as effective with their 24 h UFC significantly reduced after the procedure (1 338.41±448.06) mmol/L from (633.66±315.94) mmol/L, P=0.011). The change of 24 h UFC between the effective treatment group and ineffective group was statistically significant (P=0.020). The postoperative systolic blood pressure in the treated adenoma group was significantly lower than those of hyperplasia group (112±13) mmHg vs. (139±20) mmHg, P=0.026). Conclusions: For patients with CS-associated hypertension who are unwilling or unable to undergo surgical treatment, catheter-based adrenal ablation could improve the blood pressure and cortisol level. Catheter-based adrenal ablation could be a safe, effective, and minimally invasive therapy. However, our results still need to be validated in further large-scale studies.
Male
;
Humans
;
Cushing Syndrome/complications*
;
Hydrocortisone
;
Adrenal Gland Neoplasms/surgery*
;
Feasibility Studies
;
Blood Glucose
;
Hyperplasia/complications*
;
Hypertension/complications*
;
Adenoma/complications*
;
Body Weight
;
Catheters/adverse effects*
2.Efficacy and feasibility of catheter-based adrenal ablation on Cushing's syndrome associated hypertension.
Zhen Cheng YAN ; Nan JIANG ; He Xuan ZHANG ; Qing ZHOU ; Xiao Li LIU ; Fang SUN ; Ruo Mei YANG ; Hong Bo HE ; Zhi Gang ZHAO ; Zhi Ming ZHU
Chinese Journal of Cardiology 2023;51(11):1152-1159
Objective: To explore the value of catheter-based adrenal ablation in treating Cushing's syndrome (CS)-associated hypertension. Methods: A clinical study was conducted in patients with CS, who received catheter-based adrenal ablation between March 2018 and July 2023 in Daping Hospital. Parameters monitored were blood pressure (outpatient and 24-hour ambulatory), body weight, clinical characteristics, serum cortisol and adrenocorticotropic hormone (ACTH) at 8 am, 24-hour urinary free cortisol (24 h UFC), fasting blood glucose and postoperative complications. Procedure effectiveness was defined as blood pressure returning to normal levels (systolic blood pressure<140 mmHg (1 mmHg=0.133 kPa) and diastolic blood pressure<90 mmHg), cortisol and 24 h UFC returning to normal and improvement of clinical characteristics. The parameters were monitored during follow up in the outpatient department at 1, 3, 6, and 12 months after catheter-based adrenal ablation. Results: A total of 12 patients (aged (40.0±13.2) years) were reviewed. There were 5 males, with 5 cases of adenoma and 7 with hyperplasia from imaging studies. Catheter-based adrenal ablation was successful in all without interruption or surgical conversion. No postoperative complication including bleeding, puncture site infection, adrenal artery rupture or adrenal bleeding was observed. The mean follow up was 28 months. Compared to baseline values, body weight declined to (59.48±11.65) kg from (64.81±10.75) kg (P=0.008), fasting blood glucose declined to (4.54±0.83) mmol from (5.53±0.99) mmol (P=0.044), outpatient systolic blood pressure declined to (128±21) mmHg from (140±19) mmHg (P=0.005), diastolic blood pressure declined to (78±10) mmHg from (86±11) mmHg (P=0.041), and the mean ambulatory daytime diastolic blood pressure declined to (79±12) mmHg from (89±8) mmHg (P=0.034). Catheter-based adrenal ablation in 8 patients was defined as effective with their 24 h UFC significantly reduced after the procedure (1 338.41±448.06) mmol/L from (633.66±315.94) mmol/L, P=0.011). The change of 24 h UFC between the effective treatment group and ineffective group was statistically significant (P=0.020). The postoperative systolic blood pressure in the treated adenoma group was significantly lower than those of hyperplasia group (112±13) mmHg vs. (139±20) mmHg, P=0.026). Conclusions: For patients with CS-associated hypertension who are unwilling or unable to undergo surgical treatment, catheter-based adrenal ablation could improve the blood pressure and cortisol level. Catheter-based adrenal ablation could be a safe, effective, and minimally invasive therapy. However, our results still need to be validated in further large-scale studies.
Male
;
Humans
;
Cushing Syndrome/complications*
;
Hydrocortisone
;
Adrenal Gland Neoplasms/surgery*
;
Feasibility Studies
;
Blood Glucose
;
Hyperplasia/complications*
;
Hypertension/complications*
;
Adenoma/complications*
;
Body Weight
;
Catheters/adverse effects*
3.Comparison of coagulation function between adrenocorticotropic hormone independent Cushing syndrome and nonfunctional adrenal adenoma and its influence factors.
Wei WANG ; Jia Ning WANG ; Wei YU ; Sai Nan ZHU ; Ying GAO ; Jun Qing ZHANG
Journal of Peking University(Health Sciences) 2023;55(6):1062-1067
OBJECTIVE:
To investigate the coagulation function indicators and identify influence factors of hypercoagulability in patients with adrenocorticotropic hormone (ACTH) independent Cushing syndrome (CS).
METHODS:
In our retrospective study, the electronic medical records system of Peking University First Hospital was searched for the patients diagnosed with ACTH independent CS on discharge from January 2014 to June 2019. Nonfunctional adrenal adenoma patients were chosen as control group and matched 1 ∶1 by body mass index (BMI), gender, and discharge date. Clinical features and coagulation function indicators were compared between the two groups.
RESULTS:
In the study, 171 patients were included in each group. Compared with control group, activated partial thromboplastin time (APTT), and prothrombin time (PT) in ACTH independent CS group were significantly lower [(29.22±3.39) s vs. (31.86±3.63) s, P < 0.001; (29.22±3.39) s vs. (31.86±3.63) s, P < 0.001], and both D-dimer and fibrin degradation products (FDP) levels were significantly higher (P < 0.05). Percentage of APTT levels under the lower limit of reference range in the CS patients was significantly higher than that in nonfunctional group (21.6% vs. 3.5%, P < 0.001). Percentage of D-dimer levels over the upper limit of reference range in the CS patients was significantly higher than that in nonfunctional group (13.5% vs. 6.6%, P=0.041). There were three patients with deep venous thrombosis and one patient with pulmonary embolism in CS group, however none was in control group. The area under curve (AUC) of serum cortisol rhythm (8:00, 16:00 and 24:00) levels was negatively associated with the levels of PT (r=-0.315, P < 0.001) and APTT (r=-0.410, P < 0.001), and positively associated with FDP (r=0.303, P < 0.001) and D-dimer levels (r=0.258, P < 0.001). There were no differences in coagulation function indicators among different histopathologic subgroups (adrenocortical adenoma, adrenocortical hyperplasia, oncocytic adenoma, adrenocortical carcinoma). With Logistic regression analysis, the AUC of cortisol and glycosylated hemoglobin A1c (HbA1c) levels were independent risk factors for hypercoagulability in the ACTH independent CS patients (P < 0.05).
CONCLUSION
ACTH independent CS patients were more likely in hypercoagulable state compared with nonfunctional adrenal adenoma, especially in ACTH independent CS patients with higher levels of cortisol AUC and HbA1c. These patients should be paid attention to for the hypercoagulability and thrombosis risk.
Humans
;
Cushing Syndrome/complications*
;
Adrenocortical Adenoma/complications*
;
Adrenocorticotropic Hormone
;
Hydrocortisone
;
Retrospective Studies
;
Glycated Hemoglobin
;
Adrenal Cortex Neoplasms/diagnosis*
;
Adenoma/diagnosis*
;
Thrombophilia/complications*
4.Advances in Evaluation of Cognitive Impairment in Patients with Cushing's Disease.
Wei-Yu MAO ; Hui YOU ; Bing XING ; Hui-Juan ZHU ; Feng FENG
Acta Academiae Medicinae Sinicae 2016;38(6):735-738
Cushing's disease (CD) is a relatively rare disease,characterized by pathological hypercortisolism secondary to excessive adrenocorticotrophic hormone that is secreted by pituitary adrenocorticotrophic hormone adenoma or hyperplasia. In addition to the typical clinical symptoms such as moon face,buffalo hump,and central obesity,the CD patients may also experience mental disorders and cognitive dysfunction. This review mainly focuses on the cognitive state of CD patients,the mechanisms of cognitive impairment caused by high cortisol levels,and the imaging findings (especially magnetic resonance imaging) for the evaluation of cognitive functions.
Adenoma
;
complications
;
Cognition
;
Cognitive Dysfunction
;
complications
;
diagnosis
;
Cushing Syndrome
;
complications
;
Humans
;
Hyperplasia
;
Magnetic Resonance Imaging
;
Pituitary ACTH Hypersecretion
;
Pituitary Neoplasms
;
complications
5.Diagnosis of cyclic Cushing syndrome using the morning urine free cortisol to creatinine ratio.
Yi Sun JANG ; Ihn Suk LEE ; Jong Min LEE ; Soo A CHOI ; Gi Jun KIM ; Hye Soo KIM
The Korean Journal of Internal Medicine 2016;31(1):184-187
No abstract available.
ACTH-Secreting Pituitary Adenoma/complications/diagnostic imaging/surgery
;
Adenoma/complications/diagnostic imaging/surgery
;
Adolescent
;
Biomarkers/urine
;
Biopsy
;
*Circadian Rhythm
;
Creatinine/*urine
;
Cushing Syndrome/*diagnosis/*urine
;
Female
;
Humans
;
Hydrocortisone/*urine
;
Magnetic Resonance Imaging
;
Predictive Value of Tests
;
Tomography, X-Ray Computed
;
Treatment Outcome
;
Urinalysis
6.A functioning adrenal adenoma and pheochromocytoma in the same adrenal gland: two discrete adrenal incidentalomas.
Ga Eun PARK ; Yoon Young CHO ; Yun Soo HONG ; Su Hoon KANG ; Kyung Ho LEE ; Hyun Woo LEE ; Jae Hyeon KIM
The Korean Journal of Internal Medicine 2015;30(1):114-117
No abstract available.
Adrenal Cortex Function Tests
;
*Adrenal Cortex Neoplasms/complications/diagnosis/metabolism/surgery
;
*Adrenal Gland Neoplasms/complications/diagnosis/metabolism/surgery
;
Adrenalectomy
;
*Adrenocortical Adenoma/complications/diagnosis/metabolism/surgery
;
Biopsy
;
Cushing Syndrome/diagnosis/etiology
;
Female
;
Humans
;
Immunohistochemistry
;
*Incidental Findings
;
Middle Aged
;
*Neoplasms, Multiple Primary/complications/diagnosis/metabolism/surgery
;
*Pheochromocytoma/complications/diagnosis/metabolism/surgery
;
Predictive Value of Tests
;
Tomography, X-Ray Computed
;
Treatment Outcome
;
Tumor Markers, Biological/metabolism
7.Massive Thoracoabdominal Aortic Thrombosis in a Patient with Iatrogenic Cushing Syndrome.
Dong Hun KIM ; Dong Hyun CHOI ; Young Min LEE ; Joon Tae KANG ; Seung Seok CHAE ; Bo Bae KIM ; Young Jae KI ; Jin Hwa KIM ; Joong Wha CHUNG ; Young Youp KOH
Korean Journal of Radiology 2014;15(5):637-640
Massive thoracoabdominal aortic thrombosis is a rare finding in patients with iatrogenic Cushing syndrome in the absence of any coagulation abnormality. It frequently represents an urgent surgical situation. We report the case of an 82-year-old woman with massive aortic thrombosis secondary to iatrogenic Cushing syndrome. A follow-up computed tomography scan showed a decreased amount of thrombus in the aorta after anticoagulation therapy alone.
Aged, 80 and over
;
Anticoagulants/therapeutic use
;
Aorta, Abdominal/ultrasonography
;
Cushing Syndrome/*complications/*diagnosis
;
Electrocardiography
;
Female
;
Humans
;
Iatrogenic Disease
;
Thrombosis/*diagnosis/drug therapy/*etiology
;
Tomography, X-Ray Computed
;
Treatment Outcome
8.A Case of Congenital Adrenal Hyperplasia Mimicking Cushing's Syndrome.
Hye Jeong KIM ; Mira KANG ; Jae Hyeon KIM ; Sun Wook KIM ; Jae Hoon CHUNG ; Yong Ki MIN ; Moon Kyu LEE ; Kwang Won KIM ; Myung Shik LEE
Journal of Korean Medical Science 2012;27(11):1439-1443
Congenital adrenal hyperplasia (CAH) is characterized by decreased adrenal hormone production due to enzymatic defects and subsequent rise of adrenocorticotrophic hormone that stimulates the adrenal cortex to become hyperplastic, and sometimes tumorous. As the pathophysiology is basically a defect in the biosynthesis of cortisol, one may not consider CAH in patients with hypercortisolism. We report a case of a 41-yr-old man with a 4 cm-sized left adrenal tumorous lesion mimicking Cushing's syndrome who was diagnosed with CAH. He had central obesity and acanthosis nigricans involving the axillae together with elevated 24-hr urine cortisol level, supporting the diagnosis of Cushing's syndrome. However, the 24-hr urine cortisol was suppressed by 95% with the low dose dexamethasone suppression test. CAH was suspected based on the history of precocious puberty, short stature and a profound suppression of cortisol production by dexamethasone. CAH was confirmed by a remarkably increased level of serum 17-hydroxyprogesterone level. Gene mutation analysis revealed a compound heterozygote mutation of CYP21A2 (I173N and R357W).
17-alpha-Hydroxyprogesterone/blood
;
Acanthosis Nigricans/complications
;
Adrenal Hyperplasia, Congenital/complications/*diagnosis/drug therapy
;
Adult
;
Cushing Syndrome/diagnosis
;
DNA Mutational Analysis
;
Dexamethasone/therapeutic use
;
Glucocorticoids/therapeutic use
;
Heterozygote
;
Humans
;
Hydrocortisone/urine
;
Male
;
Mutation
;
Obesity/complications
;
Steroid 21-Hydroxylase/genetics
;
Tomography, X-Ray Computed
9.Spontaneous Rupture of a Functioning Adrenocortical Carcinoma.
Jin Ook CHUNG ; Dong Hyeok CHO ; Jae Hyuk LEE ; Dong Deuk KWON ; Dong Jin CHUNG ; Min Young CHUNG
Yonsei Medical Journal 2010;51(6):974-977
Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis, and it can be classified as either a functional or nonfunctional tumor. Affected patients usually present with abdominal pain or with symptoms related to the mass effect or hormonal activity of the tumor. Several cases of spontaneously ruptured nonfunctional adrenocortical carcinoma have been reported, but no case of a spontaneous rupture of functioning adrenocortical carcinoma has been described. We report a functioning adrenocortical carcinoma that spontaneously ruptured during a work-up.
Abdominal Pain
;
Adrenal Cortex Neoplasms/*complications/*diagnosis
;
Adult
;
Biopsy
;
Carcinoma/*complications/*diagnosis
;
Cushing Syndrome/diagnosis
;
Diagnostic Imaging/methods
;
Female
;
Hemorrhage/physiopathology
;
Hormones/metabolism
;
Humans
;
Magnetic Resonance Imaging/methods
;
Rupture, Spontaneous
;
Tomography, X-Ray Computed/methods
;
Treatment Outcome
10.A Case of Cushing's Syndrome Presenting as Endometrial Hyperplasia.
Sang Min LEE ; Jong Ryeal HAHM ; Tae Sik JUNG ; Jung Hwa JUNG ; Mi Yeon KANG ; Sun Joo KIM ; Soon Il CHUNG
The Korean Journal of Internal Medicine 2008;23(1):49-52
We describe here the case of a 39-year-old woman with a cortisol-producing adrenal adenoma and she presented with endometrial hyperplasia and hypertension without the specific characteristics of Cushing's syndrome. The patient had consulted a gynecologist for menometrorrhagia 2 years prior to her referral and she was diagnosed with endometrial hyperplasia and hypertension. Her blood pressure and the endometrial lesion were refractory despite taking multiple antihypertensives and repetitive dilation and curettage and progestin treatment. On admission, the clinical examination revealed mild central obesity (a body mass index of 22.9 kg/m2, a waist circumference of 85 cm and a hip circumference of 94cm), but there was no hirsutism and myopathy. She showed impaired glucose tolerance on an oral glucose tolerance test. The biochemical hypercortisolemia together with the prolactin and androgen levels were evaluated to explore the cause of her anovulation. Adrenal Cushing's syndrome was confirmed on the basis of the elevated urinary free cortisol (454 microgram/24h, normal range: 20-70) with a suppressed ACTH level (2.0 pg/mL, normal range: 6.0-76.0) and the loss of circadian cortisol secretion. A CT scan revealed a 3.1 cm, hyperechoic, well-marginated mass in the left adrenal gland. Ten months post-adrenalectomy, the patient had unintentionally lost 9 kg of body weight, had regained a regular menstrual cycle and had normal thickness of her endometrium.
Adrenal Cortex Neoplasms/complications/*diagnosis/surgery
;
Adrenalectomy
;
Adrenocortical Adenoma/complications/*diagnosis/surgery
;
Adrenocorticotropic Hormone/blood
;
Adult
;
Circadian Rhythm
;
Cushing Syndrome/*diagnosis/etiology/physiopathology
;
Diagnosis, Differential
;
Endometrial Hyperplasia/*diagnosis
;
Female
;
Humans
;
Hydrocortisone/secretion/urine

Result Analysis
Print
Save
E-mail